Business
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunologyHOUSTON, TX / ACCESSWIRE / January 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Amy Mahery to its Board of Directors, effective upon completion of a financing. Ms. Mahery, who currently serves as the Chief Commercial Officer of Roivant Sciences, a $9 Billion market cap biopharmaceutical company, is a well-established biopharmaceutical industry veteran with more than 20 years of experience and commercial expertise working with large and small companies in common and rare conditions, and across multiple therapeutic areas. Over the course of her distinguished career, she has held diverse global and U.S. commercial leadership roles spanning sales, marketing, and market access where she has been involved in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunology. During her tenures at market-leading companies she has been responsible for developing high-impact commercial strategies that delivered profitable growth across multibillion-dollar product portfolios on a global scale. Additionally, in her work at emerging biopharma companies, she has built commercial capabilities from the startup phase to enable the commercialization of first-in-class and best-in-class assets.Faith L. Charles, Chair of the CNS Pharmaceuticals Board of Directors commented, \"We are incredibly pleased to welcome Amy to the Board. She is a proven commercial leader with a wealth of knowledge and expertise amassed over the course of her 20+ years in the industry. As the Company continues to advance Berubicin toward completion of its global potentially pivotal clinical trial and potential regulatory approval, her guidance, insight and vast pharma industry network will truly be invaluable. We remain committed to serving GBM patients in desperate need of a treatment, and look forward to leveraging Amy's extensive experience and commercial leadership to assist in positioning the Company...